Oregon Urology Institute

Az itteni vizsgálatok

Miről szól a helyszín 16 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Prosztatarák13 vizsgálat
• Hólyagrák3 vizsgálat

Fázis

• 3. fázis9 vizsgálat
• 2. fázis4 vizsgálat
• 2/3. fázis1 vizsgálat

Állapot

• Toboroz8 vizsgálat
• Fut, nem toboroz6 vizsgálat
• Lezárult2 vizsgálat

Fő szponzor

• Janssen Research & Development, LLC4 vizsgálat
• Novartis Pharmaceuticals3 vizsgálat
• Pfizer2 vizsgálat
• Bayer1 vizsgálat
• Candel Therapeutics, Inc.1 vizsgálat
• és még 5

Futó vizsgálatok

• Toboroz

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás

• Toboroz

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· 2. fázis· Tyra Biosciences, Inc· Forrás

  Contact: Gina Risdall

• Toboroz

  Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  NCT06780670· 2/3. fázis· Novartis Pharmaceuticals· Forrás

  Contact: Maxim Dimarco

• Toboroz

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· 2. fázis· CG Oncology, Inc.· Forrás

  Contact: Katareanna Jeudy

• Toboroz

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· 3. fázis· Novartis Pharmaceuticals· Forrás

  Contact: Victoria Evans

• Fut, nem toboroz

  A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

  NCT05849298· 2. fázis· Novartis Pharmaceuticals· Forrás

• Toboroz

  Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

  NCT06134232· 2. fázis· Dendreon· Forrás

  Contact: Bryan Mehlhaff, MD

• Fut, nem toboroz

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· 3. fázis· Janssen Pharmaceutica N.V., Belgium· Forrás

• Fut, nem toboroz

  A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

  NCT04122976· Bayer· Forrás

• Fut, nem toboroz

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· 3. fázis· Janssen Research & Development, LLC· Forrás

• Fut, nem toboroz

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· 3. fázis· Pfizer· Forrás

• Fut, nem toboroz

  Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

  NCT01436968· 3. fázis· Candel Therapeutics, Inc.· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Prosztatarák5 toboroz
• Hólyagrák3 toboroz

Lezárt vizsgálatok

• Lezárult

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Sumitomo Pharma America, Inc.· Forrás

• Lezárult

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· 3. fázis· Pfizer· Forrás